Sponsor: Kangpu Biopharmaceuticals, Ltd.
Protocol KPG-818-HEM-101. A phase 1 study of lenalidomide analog KPG-818 in subjects with hematologic malignancies. Included diagnoses are: Multiple Myeloma, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse Large B-cell Lymphoma, Adult T-cell Leukemia-Lymphoma, Chronic Lymphocytic Leukemia, and indolent lymphomas.
For more information please contact the clinical research department: 631-675-5075